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Abstract
Diagnosis of fungal pneumonia (FP) in critically ill patients is challenging. Circulating biomarkers for the diagnosis of FP have limitations
and the combination of different assays in serum samples and directly from the target organ may further improve the diagnosis of FP.
We prospectively assessed the diagnostic utility of paired galactomannan (GM) in bronchoalveolar lavage ﬂuid (BAL) and serum GM and
(1ﬁ3)–b–D-glucan (BG) assays in critically ill patients at risk of FP. Patients with FP were classiﬁed according to European Organisation
for Research and Treatment of Cancer-Mycoses Study Group criteria, with modiﬁcations. Out of 847 admissions, 51 patients were eligi-
ble. There were nine invasive aspergillosis (IA) cases (four proven, ﬁve probable), three proven Pneumocysitis jirovecii pneumonia (PJP)
cases and one mixed FP case (probable IA and proven PJP). The diagnostic accuracy as given by the area under the receiver operating
characteristic curve in IA cases (proven and probable) for GM in BAL was 0.98 (95% CI, 0.94–1.00), whilst for GM and BG in serum it
was 0.85 (95% CI, 0.74–0.96) and 0.815 (95% CI, 0.66–0.96), respectively. For IA cases (proven and probable) AUC for GM in BAL was
signiﬁcantly higher than GM and BG in serum (p 0.025 and p 0.032, respectively). In one of four proven and one of six probable IA
cases, GM in serum remained negative, whereas GM in BAL was positive. In patients with IA, GM (90%) and BG (80%) appeared a mean
of 4.3 days (range, 1–10 days) before Aspergillus was cultured. GM detection in BAL appears to improve the diagnosis of IA in critical
patients.
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Introduction
Fungal pneumonia (FP) is a signiﬁcant cause of morbidity and
mortality in medical intensive care unit patients; Aspergillus
species are the most prevalent pathogens. Invasive aspergillo-
sis (IA) in non-neutropenic patients in intensive care units
(ICU) is increasing [1]. Other fungal pathogens such as Cryp-
tococcus, Fusarium, Scedosporium, Zygomycetes and Pneumocys-
tis jirovecii are emerging as aetiological agents in this setting,
although they are less common.
Diagnosis of FP in critically ill patients is challenging
because of non-speciﬁc clinical presentation, poor diagnostic
yield of cultures and non-speciﬁcity and delay of radiological
imaging [1,2]. The cornerstone for diagnosis of FP is biopsy
of deep tissues, but this aggressive diagnostic approach is
often precluded in critically ill patients [3].
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Conventional diagnostic tests (cultures and direct exami-
nation) of respiratory tract samples have low diagnostic yield
[2]. With the advent of new culture independent tools such
as galactomannan (GM) and (1ﬁ3)–b–D-glucan (BG) testing,
the diagnosis of invasive fungal disease (IFD) in adult neu-
tropenic patients and haematopoietic stem cell transplant
recipients has improved [3]. Few data are available on their
performance in the setting of ICU patients. The use of GM
detection in bronchoalveolar lavage ﬂuid (BAL) as a means of
establishing early diagnosis of IA in critically ill patients at risk
is promising [4]. However, data on the performance of BG
in medical ICU patients are scarce [5,6].
Biomarkers have been used as screening tools in popula-
tions at high risk of IFD such as haematology patients [7–9].
In clinical practice, another approach is to use biomarkers as
adjuncts in patients at high risk of IFD with compatible clini-
cal syndromes and in this setting available retrospective BG
data are scarce [5,10–12].
We conducted this prospective study to evaluate and
compare the diagnostic performance of GM in BAL with GM
and BG in serum samples in a cohort of critically ill patients
with mechanical ventilation and FP.
Materials and Methods
Patients
Attending ICU physicians requested a diagnostic bronchos-
copy when clinically judged necessary. Patients with a clinical
syndrome compatible with pneumonia needed to have at
least two of the following criteria: fever, worsening gas
exchange, pulmonary inﬁltrates or dyspnoea. In addition, at
least one host factor (cirrhosis, HIV, cancer receiving chemo-
therapy, patients with a haematological malignancy, steroid
use, T-cell immunosuppressant or solid organ transplant
recipients) was required. Upon inclusion, paired synchronous
BAL and serum samples were obtained.
Antifungal treatment was started at the discretion of the
attending physician.
The study was approved by the Ethics Committee.
Case deﬁnitions of IA and P. jirovecii pneumonia (PJP)
Proven and probable IA diagnoses were based on the modi-
ﬁed deﬁnitions of De Pauw et al. [13], excluding the detec-
tion of GM in BAL, and GM and BG in serum samples.
We deﬁned PJP based on positive microscopy stain with
monoclonal antibodies (Monoﬂuo; Bio-Rad Laboratories,
Marnes La Coquette, France) in the BAL samples, and the
presence of at least four of the following criteria: bilateral
interstitial inﬁltrates, hypoxia, fever, dyspnoea, cough, lactate
dehydrogenase >230 U/L, CD4 cell £200 cells/mm3 and
appropriate response to speciﬁc treatment for PJP.
Diagnostic bronchoscopy with BAL
The sampling area was selected on the basis of the inﬁltrate
or consolidation location on the chest radiograph (100–
150 mL of 0.9% sterile saline were instilled). Biopsies were
obtained whenever feasible. BAL ﬂuid samples were submit-
ted for direct wet mount preparation (with 20% potassium
hydroxide and 40% dimethyl sulfoxide), gram staining, Ziehl
smear and staining with monoclonal antibodies for P. jirovecii,
and for bacterial, fungal, mycobacterial and viral cultures.
GM and BG testing
GM (Platelia Aspergillus; Bio-Rad Laboratories) and BG
(Fungitell; Associates of Cape Cod Inc, Falmouth, MA,
USA) were performed according to the manufacturer¢s
recommendations for testing serum (BG and GM) and BAL
(GM) samples as described elsewhere [4,7].
Statistical analysis
Measurable and categorical variables were, respectively,
described with mean, standard deviation (SD) and range, or
frequency distribution. Continuous variables were compared
with the Mann–Whitney U-test. Relevant summary diagnostic
parameters, namely sensitivity (S), speciﬁcity (SP), positive
and negative predictive values (PPV, NPV), positive and nega-
tive likelihood ratios (PLR, NLR) and efﬁciency (E), were cal-
culated. The optimal cut-offs were determined with receiver
operating characteristic (ROC) curves and areas under the
curve (AUCs) were estimated to analyse the discriminatory
power. Comparisons between AUCs were performed using
the method of Hanley and McNeil [14]. All estimations were
reported with 95% conﬁdence intervals (CI). Paired BAL and
serum samples were analysed.
Results
Over a period of 21 months 847 patients were admitted to
the ICU; 191 (22.5%) had pneumonia. Of these, 93 (48.6%)
had host factors for IFD and 51 (26.7%) met the criteria for
inclusion (13 case patients in the IFD group and 38 patients
in the control group without evidence of IFD) (Table 1). The
overall prevalence of IFD was 25.5%.
Thirty-nine patients (76.4%) had at least two predisposing
deﬁned host and/or risk factors. The reasons for ICU admis-
sion were: acute respiratory failure (48 patients, of these 31
had pneumonia with septic shock), septic shock associated
with acute pancreatitis (1), faecal peritonitis (1) and acute
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pyelonephritis (1). The rate of necropsies was 21.73% (5/23).
Only three patients were treated with voriconazole, 1, 3 and
7 days, respectively, prior to BAL.
BAL and sera were obtained at a mean of 9.16 days
(range, 1–66 days) after ICU admission (50% and 80% in a
range between 1–3 days and 1–10 days, respectively).
BAL GM levels
The diagnostic accuracy as given by AUC for all IA case
patients (proven and probable) was 0.981 (95% CI, 0.94–1.0)
and for proven IA cases was 0.968 (95% CI, 0.92–1.0), as
shown in Fig. 1(a,b). The median of GM in the control group
(which also included the three case patients with PJP) was
0.13 (interval quartile range (IQR), 0.095–0.16). The mean
GM level for the six neutropenic control patients was not
different from the mean value for the 35 non-neutropenic
control patients, 0.146 (SD, 0.08; IQR, 0.11–0.15) and 0.231
(SD, 0.06; IQR, 0.09–0.17), respectively (p = 0.377).
Table 2 shows the performance of GM in BAL ﬂuid for
the diagnosis of proven IA and of proven and probable IA
case patients with the use of different GM cut-off values.
The best diagnostic performance of GM for both proven and
probable IA cases was obtained with a GM cut-off ‡1. Two
case patients (20%), both with probable IA, had GM levels
<1; one of these patients had received voriconazole treat-
ment for 3 days before sampling. One patient in the control
group presented a GM value of 1.516.
BAL ﬂuid culture and microscopy
Culture and microscopy were performed in all BAL ﬂuid
samples (10 IA cases and 41 control patients). Ten (100%) of
the BAL samples from case patients were culture positive
for Aspergilllus species (nine A. fumigatus, and one A. fumigatus
and A. niger). No BAL samples from the control patients
tested culture positive for Aspergillus species. In patients with
IA, GM (90%) and BG (80%) appeared a mean of 4.3 days
(range, 1–10 days) before Aspergillus was grown. Five (50%)
BAL samples from IA case patients had positive direct
microscopy (septate hyphae) and four patients had positive
P. jirovecii stains.
Serum GM levels
The serum GM diagnostic accuracy as given by AUC for all IA
case patients was 0.854 (95% CI, 0.74–0.96) and for proven
IA cases was 0.835 (95% CI, 0.65–1.0), as shown in Fig. 1(a,b).
The median of the GM levels for both the control group
TABLE 1. Characteristics of critically ill patients at risk of invasive fungal disease (IFD)
Patients
Proven invasive
aspergillosis
(n = 4)
Probable invasive
aspergillosis
(n = 6)
Proven Pneumocystis
jirovecii pneumoniaa
(n = 4) Non-IFD (n = 38) Total (n = 51)
Mean age, years (SD) 63.3 (±13.7) 65.6 (±8.0) 59.5 (±15.5) 55.5 (±15.66) 57.5 (±15.1)
Female/male 3/1 3/3 1/3 11/27 17/34
No. deaths (%) 3 (75) 4 (66.6) 3 (75) 14 (36.8) 23 (45.1)
Mean APACHE II/SAPS II 18.3/47.6 31.4/61.4 24.3/61 23.3/49.4 23.8/51.26
Mechanical ventilation, mean days 17 12 13 18.1 17
ICU stay, mean days (range) 12.25 (6–15) 11.6 (2–28) 10 (6–20) 18.5 (1–66) 16.8 (1–66)
Hospital stay, mean days (range) 19.8 (15–28) 35 (7–76) 33.5 (8–56) 40.9 (4–136) 38.1 (4–136)
Acute renal failure with ERPT 2 3 1 10 16
Steroidsb (%) 3 (75) 6 (100) 4 (100) 24 (63.2) 36 (70.6)
Neutropenia (%) 0 0 0 6 (15.8) 6 (11.8)
Haematological disease (%) 0 0 0 3 (7.9) 3 (5.9)
SCT autologos/allogenic 0/0 0/0 0/0 1/0 1/0
Non-haematological 4 6 4
COPD 1 2 1 5 8
Renal transplants 1 0 0 3 4
HIV 1 1 3 4 8
Cirrhosis 0 1 0 1 2
Systemic diseases 1 2 1 2 6
Solid cancer 1 1 1 5 8
Chronic renal failure 2 3 1 14 20
Clinical criteria
Tracheobronchitis 0 1 0 0 1
Lung nodules 4 4 0 2 10
Lung nodule with halo sign,
bilateral inﬁltrates and CNS
focal lesions
0 1 1 0 1
Aspergillus cultures 4/4 6/0 1/0 0/0 7/4
BAL/biopsy or necropsy
BAL GM index, mean (range) 12.4 (4.3–30) 6.9 (0.44–30.2) 0.20 (0.02–0.46) 0.21 (0.04–1.56) 1.96 (0.02–30.19)
Serum GM index, mean (range) 1.2 (0.19–2.17) 0.56 (0.13–1.15) 0.37 (0.08–0.9) 0.22 (0.06–1.1) 0.35 (0.05–2.17)
Serum BG pg/mL, mean (range) 1076.4 (84.3–2294.6) 990.94 (32–3071) 1023.2 (423–2229) 133.27 (1.4– 2625) 336.8 (1.4–3071)
APACHE II, Acute Physiology and Chronic Health Evaluation; SAPS II, Simpliﬁed Acute Physiology Score II; ICU, intensive care unit; ERPT, extra-renal puriﬁcation techniques;
SCT, stem cell transplantation; COPD, chronic obstructive pulmonary disease; HIV, human immunodeﬁciency virus; CNS, central nervous system; BAL, bronchoalveolar
lavage; GM, galactomannan; BG, (1-3) b-D-Glucan.
aOne HIV patient with proven P. jirovecii pneumonia had probable invasive aspergillosis.
bMinimum dose of 0.3 mg/kg/day of prednisone equivalent for >3 weeks.
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and the three cases with PJP was 0.13 (IQR, 0.11–0.26). The
mean GM level for the six neutropenic control patients was
not different from the mean value for the 35 non-neutropenic
control patients: 0.32 (SD, 0.39; IQR, 0.12–0.27) and 0.203
(SD, 0.21; IQR, 0.10–0.26), respectively (p = 0.484).
Table 2 shows the performance of GM in serum samples
for the diagnosis of all IA cases with the use of different GM
cut-off values. In our population the best diagnostic perfor-
mance of GM was obtained with a GM cut-off ‡0.4, a value
very similar to the recommended cut-off. Four case patients
(patients 64, 65, 91 and 120 shown in Table 4) had GM
blood levels <0.4. One of these had been previously treated
with voriconazole and another had tracheobronchitis. How-
ever, BAL GM was positive in two of these patients with
(a) (b) (c)
FIG. 1. Area under the curve (AUC) of receiver-operating curves (ROC) for: (a) all invasive aspergillosis (IA) cases, proven and probable; (b)
proven IA cases; and (c) all invasive fungal disease cases (IA and P. jirovecii pneumonia). In case of IA (proven and probable), the AUC for GM in
BAL was signiﬁcantly higher than GM and BG in serum (p 0.0258 and p 0.0322, respectively). In cases of proven IA, there was no signiﬁcant dif-
ference between the AUC for GM in BAL when compared with the AUC for GM and BG in serum (p 0.203 and p 0.159, respectively).
TABLE 2. Performance of GM in BAL and serum in IA case patients
Cutoff
Sensitivity %
(95% CI)
Speciﬁcity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
PLR
(95% CI)
NLR
(95% CI) Efﬁciency %
BAL GM
Proven IA
‡0.5 100 (87.5–100) 85.11 (73.86–96.35) 36.36 (3.39–69.34) 100 (98.75–100) 6.71 (3.39–13.3) – 86.27
‡1 100 (87.5–100) 89.36 (79.48–99.24) 44.44 (6.42–82.46) 100 (98.81–100) 9.4 (4.1–21.53) – 90.20
‡4 100 (87.5–100) 95.74 (88.91–100) 66.67 (20.61–100) 100 (98.89–100) 23.5 (6.05–91.21) – 96.08
‡8 50 (0–100) 97.87 (92.68–100) 66.67 (0–100) 95.83 (89.14–100) 23.5 (2.68–206.3) 0.51 (0.19–1.36) 92.16
Proven + Probable IA
‡0.5 80 (50.2–100) 92.6 (83.4–100) 72.7 (41.8–100) 95 (87–100) 10.9 (3.5–33.9) 0.2 (0.06–0.7) 90.2
‡1 80 (50.2–100) 97.5 (91.6–100) 88.8 (62.8–100) 95.2 (87.6–100) 32.8 (4.6–232.9) 0.2 (0.06–0.7) 94.1
‡1.5 70 (36.6–100) 97.5 (91.6–100) 87.5 (58.3–100) 93.0 (84.2–100) 28.7 (3.9–207.4) 0.3 (0.1–0.7) 92.1
‡2 70 (36.6–100) 100 (98.7–100) 100 (92.8–100) 93.1 (84.6–100) – 0.3 (0.1–0.7) 94.1
Serum GM
Proven IA
‡0.2 75 (20.06–100) 61.7 (46.74–76.6) 14.29 (0–31.63) 96.67 (88.58–100) 1.96 (1.0–3.84) 0.41 (0.07–2.25) 62.75
‡0.4 50 (0–100) 82.98 (71.17–94.7) 20 (0–49.79) 95.12 (87.31–100) 2.94 (0.92–9.42) 0.60 (0.22–1.62) 80.39
‡0.5 50 (0–100) 85.11 (73.86–96.3) 22.22 (0–54.94) 95.24 (87.61–100) 3.36 (1.02–11.0) 0.59 (0.22–1.58) 82.35
‡1 50 (0–100) 95.74 (88.91–100) 50 (0–100) 95.74 (88.91–100) 11.75 (2.2–62.6) 0.52 (0.2–1.39) 92.16
‡2 50 (0–100) 100 (98.94–100) 100 (75–100) 95.92 (89.36–100) – 0.5 (0.19–1.33) 96.08
Proven + Probable IA
‡0.3 60 (24.6–95.3) 80.4 (67.1–93.8) 42.8 (13.3–72.3) 89.1 (77.8–100) 3.08 (1.3–6.8) 0.50 (0.2–1.0) 76.4
‡0.4 60 (24.6–95.3) 90.2 (79.9–100) 60 (24.6–95.3) 90.2 (79.9–100) 6.15 (2.1–17.7) 0.44 (0.2–0.9) 84.3
‡0.5 50 (14.0–85.9) 90.2 (79.9–100) 55.5 (17.5–93.5) 88.1 (77.1–99.0) 5.13 (1.6–15.6) 0.55 (0.3–1.0) 82.3
‡0.7 40 (4.6–75.3) 92.6 (83.4–100) 57.1 (13.3–100) 86.3 (75.0–97.6) 5.47 (1.4–20.6) 0.65 (0.3–1.1) 82.3
‡1 30 (0–63.4) 97.5 (91.6–100) 75 (20.0–100) 85.1 (73.8–96.3) 12.3 (1.4–106.1) 0.7 (0.4–1.1) 84.3
GM, galactomannan; BAL, bronchoalveolar lavage; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio;
NLR, negative likelihood ratio; IA, invasive aspergillosis.
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proven IA and in one patient with probable IA. Three
patients in the control group presented values ‡0.4: two of
them had co-synchronous Acinetobacter baumannii and Entero-
coccus faecalis bacteraemias. The third patient had PJP and
chronic renal failure.
Serum BG levels
The diagnostic accuracy as given by AUC for all IA case
patients was 0.815 (95% CI, 0.67–0.96), for proven IA cases
was 0.867 (95% CI, 0.74–0.99) and for all IFD patients was
0.873 (95% CI, 0.76–0.99), as shown in Fig. 1(a,b,c)). The
mean of the BG levels for all case patients with IFD was
932.05 pg/mL (SD, 1004.4; IQR, 178.5–1448.0). The mean
BG level for the six neutropenic control patients was not dif-
ferent from the mean value for the 32 non-neutropenic con-
trol patients: 64.31 (SD, 56.53; IQR, 33.72–61.6) and 146.2
(SD, 462.15; IQR, 22.0–79.0), respectively (p 0.378).
Table 3 shows the performance of BG in serum samples
for the diagnosis of IA and all IFD cases with the use of dif-
ferent BG cut-off values. The best diagnostic performance of
BG for IFD and IA (proven and probable) was obtained with
a BG cut-off ‡80. Two case patients had BG serum levels
<80, one of them had been treated with voriconazole prior
to diagnosis (Table 4). Eight patients in the control group
presented values ‡80: three of them had co-synchronous
Staphylococcus epidermidis and one Enterococcus faecalis bac-
teraemia; and one other patient had faecal peritonitis with
surgery in the previous week. No known potential causes of
false BG reactivity were identiﬁed in three other patients.
Combination of serum GM and BG levels
Two proven IA cases with GM levels £0.4 shown in Table 4
(numbers 64 and 120) had positive BG in serum samples and
therefore upgraded the AUC, SP, PPV, PLR and E to: 0.861
(95% CI, 0.72–0.99), 95.12 (95% CI, 87.31–100), 75.0 (95%
CI, 38.74–100.0), 12.3 (95% CI, 2.9–52.1) and 88.24%,
respectively, although these differences were not signiﬁcant
statistically.
Discussion
The current study reﬂects a utility analysis in a tertiary care
facility and represents real world observations. It has limita-
tions because it was physician driven (based on clinical suspi-
cion of IFD) in a cohort of critically ill patients at particular
high risk: this explains the high incidence of IFD. Other limi-
tations are the relatively small sample size and the autopsy
rate of 21.8% [15]. The timing of sampling was not protocol
deﬁned.
In a seminal autopsy-driven study in ICU patients with the
use of paired GM assays in BAL ﬂuid and serum samples, the
reported sensitivity and speciﬁcity in BAL (cut-off 0.5) were of
88% and 87%, respectively, but the positive and negative
predictive values were not assessed [4]. Our study is in line
with the results reported by Meersseman et al. [4] as all the
diagnostic parameters for the diagnosis of IA improve signiﬁ-
cantly, as shown in our cohort by the AUC with the GM assay
in BAL ﬂuid when compared with paired GM serum assays.
TABLE 3. Performance of BG in serum
Cut-off
Sensitivity %
(95% CI)
Speciﬁcity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI) PLR (95% CI) NLR (95% CI) Efﬁciency %
Serum BG
Proven IA
‡70 100 (87.5–100.0) 65.96 (51.35–80.57) 20 (0.0–40.03) 100 (98.33–100) 2.94 (1.97–4.37) – 68.63
‡80 100 (87.5–100.0) 70.21 (56.1–84.35) 22.22 (0.24–44.21) 100 (98.48–100) 3.36 (2.16–5.21) – 72.55
‡120 75 (20.1–100.0) 72.34 (58.49–86.19) 18.75 (0.0–41.0) 97.14 (90.47–100) 2.71 (1.31–5.63) 0.35 (0.1–1.9) 72.55
‡150 75 (20.1–100.0) 74.47 (60.94–88.0) 20.00 (0.0–43.58) 97.22 (90.47–100) 2.94 (1.39–6.2) 0.34 (0.06–1.85) 74.51
‡450 75 (20.1–100.0) 87.23 (76.63–97.84) 33.33 (0.0–69.69) 97.62 (91.82–100) 5.88 (2.3–15.0) 0.29 (0.05–1.57) 86.27
Proven IA + Proven P. jirovecii
‡70 100 (93.75–100) 72.09 (57.52–86.66) 40 (16.03–63.97) 100 (98.39–100) 3.58 (2.22–5.79) – 76.47
‡80 100 (93.75–100) 76.74 (62.95–90.53) 44.44 (18.71–70.18) 100 (98.48–100) 4.30 (2.5–7.4) – 80.39
‡120 87.5 (58.33–100) 79.07 (65.75–92.39) 43.75 (16.32–71.18) 97.14 (90.19–100) 4.18 (2.21–7.91) 0.16 (0.03–1.0) 80.39
‡400 87.5 (58.33–100) 93.02 (84.25–100) 70.0 (36.6–100) 97.56 (91.62–100) 12.54 (4.08–38.5) 0.13 (0.02–0.84) 92.16
Proven IA + Probable IA
‡50 90 (66.41–100) 48.78 (32.26–65.3) 30.0 (11.93–48.07) 95.24 (83.75–100) 1.76 (1.22–2.53) 0.21 (0.03–1.35 56.86
‡60 80 (50.21–100) 60.98 (44.82–77.13) 33.33 (12.39–54.28) 92.59 (80.86–100) 2.05 (1.25–3.35) 0.33 (0.09–1.16) 64.71
‡80 80 (50.21–100) 75.61 (61.25–89.97) 44.44 (18.71–70.18) 93.94 (84.28–100) 3.28 (1.76–6.11) 0.26 (0.08–0.92) 76.47
‡175 70 (36.6–100) 85.37 (73.33–97.4) 53.85 (22.9–84.79) 92.11 (82.22–100) 4.78 (2.06–11.1) 0.35 (0.14–0.91) 82.35
‡385 60 (24.64–95.3) 87.8 (76.57–99.04) 54.55 (20.57–88.52) 90 (79.45–100) 4.92 (1.87–12.9) 0.46 (0.21–0.98) 82.35
Proven IA + Probable IA + Proven P. jirovecii
‡60 84.62 (61.16–100) 65.79 (49.39–82.19) 45.83 (23.82– 67.85) 92.59 (80.86–100) 2.47 (1.5–4.07) 0.23 (0.06–0.85) 70.59
‡80 84.62 (61.16–100) 81.58 (67.94–95.22) 61.11 (35.81–86.41) 93.94 (84.28–100) 4.59 (2.26–0.33) 0.19 (0.05–0.68) 82.35
‡120 76.92 (50.17–100) 84.21 (71.3–97.12) 62.50 (35.65–89.35) 91.43 (80.73–100) 4.87 (2.21–10.76) 0.27 (0.1–0.75) 82.35
‡170 76.92 (50.17–100) 89.47 (78.4–100) 71.43 (44.19–98.66) 91.89 (81.75–100) 7.31 (2.76–19.35) 0.26 (0.1–0.70) 86.27
BG, (1ﬁ3)–b–D-glucan; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; IA,
invasive aspergillosis.
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Other studies with the detection of GM in BAL ﬂuid using
different cut-off values (from ‡0.5 to ‡1.0) show sensitivities
and speciﬁcities ranging from 85% to 100%, namely in haema-
tology patients [16–18], solid organ transplant recipients [19]
and non-immunocompromised patients [20]. The reported
sensitivity in lung transplant recipients (61%) is signiﬁcantly
lower than in other subpopulations [21]. All these studies have
reported high NPV in line with the values reported herein, but
do not provide any data on the diagnostic performance of GM
in BAL ﬂuid in comparison with paired serum samples. An
exception is the study of Maertens et al. [22], who provided
results from 10 neutropenic and 19 non-neutropenic patients
with proven IA showing that overall, determination of GM in
BAL ﬂuid had higher sensitivity than serum testing.
However, the comparison of the different studies is difﬁ-
cult because the timing of sampling is not equivalent, nor is
the impact of antifungal treatment deﬁned. Additionally, the
amount of saline instilled in the BAL procedure varies
between studies [4,16–21].
High GM levels in BAL ﬂuid were observed in one of our
patients in the control group who had negative direct exami-
nation and culture in BAL ﬂuid. The patient recovered with-
out antifungal treatment and consequently IFD could be
reasonably excluded. High GM levels in BAL testing have
been reported in patients colonized with Aspergillus [21] and
Penicillium spp. [19]. GM assay can also cross-react with Alter-
naria and Paecilomyces spp. [23]. Currently Persat et al. have
reported that in patients colonized with large amounts of
Candida albicans in BAL ﬂuid there is an association with high
levels of GM (20th European Congress of Clinical Microbiol-
ogy and Infectious Diseases, abstract # P846).
One of the problems observed in the detection of GM in
serum is the existence of false positive results that decrease
the speciﬁcity of the assay, as seen in three patients in the
control group: two who had co-synchronous A. baumannii
and E. faecalis bacteraemia, which are both known to be
associated with false positive GM results [23,24], and a third
patient (Table 4, patient number 95) with a fatal outcome
for whom no necropsy study was available and no known
cause of false reactivity could be identiﬁed.
Data on the performance of BG in ICU patients are scarce
[5] and conﬂicting as it has been reported that serum BG
levels do not show a correlation with the presence of IFD,
and do not appear to be speciﬁc (with the use of a cut-off of
20 pg/mL) [6]. In our subjects, there were eight control
patients with high BG levels but without IFD. Four such patients
had co-synchronous gram-positive bacteraemia and one other
patient had faecal peritonitis, which are recognized as potential
sources of false positive BG results [6,7,23–25]. Such condi-
tions were not identiﬁed in any of the three other patients.
In our cohort the combination of GM and BG in serum
samples upgraded the speciﬁcity, PPV and efﬁciency, although
this was not signiﬁcant statistically, as has previously been
reported [7,26].
Direct examination of BAL ﬂuid enabled the diagnosis of
PJP and in these patients the levels of BG were high, as has
previously been reported [27].
In conclusion, data presented herein are in line with
another published report [4] and suggest that a GM index
value ‡1.0 in BAL ﬂuid supports and improves the diagnosis
of IA in critical care patients. Our data suggest that BG in
the setting of non-surgical ICU patients is a non-invasive
diagnostic tool with efﬁciency, sensitivity and speciﬁcity
above 80% for the diagnosis of FP in critical patients at risk,
and also with high negative predictive value (93%). Evidence-
based prospective studies are needed for further evaluation
of the usefulness of BG.
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